SIEMENS HEALTH ADR/0,50

PLEASANTON, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- InkSpace Imaging, a leader in MRI coil innovation, today announced that the United States (US) Food and Drug Administration (FDA) has cleared InkSpace Imaging's next-generation 1.5 Tesla (1.5T) 24-channel MR coil for Siemens Healthineers Magnetom MRI scanners.» Mehr auf globenewswire.com

– Combines Profound's TULSA-PRO ® and Siemens Healthineers' Magnetom Free.Max – – Supports the Modern Treatment Pathway that allows for more accurate and precise diagnosis, treatment, and follow-up – – Aligns well with CMS 2025 Final Rule establishing Urology APC Level 7 reimbursement for TULSA procedure at all 3 sites of service – TORONTO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that it has entered into a definitive co-sales and co-marketing agreement with Siemens Healthineers, a global leader in medical technology, pursuant to which the companies will commercialize a new MRI-guided prostate therapy solution which combines Profound's TULSA-PRO® system and consumables with Siemens Healthineers' Magnetom Free.Max magnetic resonance (“MR”) scanner.1 The Transurethral Ultrasound Ablation (“TULSA”) procedure, performed using Profound's TULSA-PRO® system, employs real-time MR guidance for precision to preserve prostate disease patients' urinary continence and sexual function, while killing the targeted prostate tissue via a precise sound absorption technology that gently heats it to kill temperature (55-57°C). TULSA-PRO® enables surgeons to ablate whole- or partial-gland prostate tissue in patients with low-, intermediate, or high-risk prostate cancer; with benign prostatic hyperplasia (“BPH”); as well as those prostate cancer patients on active surveillance seeking treatment of their cancer and relief from their symptoms of BPH.» Mehr auf globenewswire.com

Recent underperformance is likely due to below-expectations revenue, mixed margins, and lower fiscal 2025 guidance, despite strong imaging and radiation oncology performance. Imaging remains a major growth driver, as new medical interventions and screening programs drive screening demand and tools like AI become increasingly vital. Fiscal 2025 guidance was modestly disappointing, but long-term growth in imaging, oncology, and image-guided therapies supports a positive outlook.» Mehr auf seekingalpha.com